Skip to main content

Table 1 Demographics and baseline disease characteristics

From: Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

  Galcanezumab 120 mg (N = 261) Placebo (N = 259)
Age, years 37.2 (9.3) 36.8 (9.8)
Females, n (%) 188 (72.0) 196 (75.7)
Race, n (%)
 Asian 239 (91.6) 239 (92.3)
 White 22 (8.4) 20 (7.7)
Body mass index, kg/m2 23.4 (3.8) 22.5 (3.2)
Region, n (%)
 China 198 (75.9) 198 (76.4)
 India 41 (15.7) 41 (15.8)
 Russia 22 (8.4) 20 (7.7)
MHDs per month, n (%) 8.2 (2.8) 8.3 (2.7)
MHDs with acute medication use per month 5.4 (4.9) 4.9 (4.5)
Migraine frequency, n (%)
  < 8 119 (45.6) 113 (43.6)
  ≥ 8 142 (54.4) 146 (56.4)
Duration of migraine illness, years 12.8 (9.2) 12.4 (8.2)
ICHD MHDs per month, n (%) 6.3 (3.3) 6.3 (3.2)
Headache days per month, n (%) 9.1 (3.3) 9.1 (2.9)
Migraine attacks per month, n (%) 5.5 (1.9) 5.6 (1.7)
MSQ score
 Total 61.7 (15.8) 62.1 (15.7)
 Role Function-Restrictive 56.0 (15.2) 57.2 (15.2)
 Role Function-Preventive 66.2 (18.5) 65.9 (17.8)
 Emotional Function 69.0 (22.2) 68.5 (21.9)
PGI-S 4.4 (1.3) 4.3 (1.3)
MIDAS total score 47.7 (37.2) 45.6 (38.6)
≥ 1 prior migraine medication, n (%) 112 (42.9) 120 (46.3)
  1. Data are presented as mean (standard deviation) unless otherwise specified
  2. ICHD International Classification of Headache Disorders, MHD Migraine headache day, MIDAS Migraine Disability Assessment, MSQ Migraine Specific Quality of Life Questionnaire, N Number of patients in the analysis population, n number of patients within each specific category, PGI-S Patient Global Impression of Severity